Why Moderna Stock Skyrocketed Today

Moderna and Merck announced positive Phase 3 clinical trial results for intismeran, an mRNA-based cancer therapy designed to activate anti-tumor immune responses in melanoma patients. The experimental treatment met its primary endpoint of recurrence-free survival when combined with Merck's Keytruda immunotherapy. The companies plan to present additional data and seek regulatory approval, positioning them to capture a larger share of the $275 billion global oncology market by 2030.